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Abstract. Site-directed mutagenesis studies have sug-
gested that additional peptide information in the cen-
tral cell-binding domain of fibronectin besides the min-
imal Arg-Gly-Asp (RGD) sequence is required for its
full adhesive activity. The nature of this second, syn-
ergistic site was analyzed further by protein chemical
and immunological approaches using biological assays
for adhesion, migration, and matrix assembly. Frag-
ments derived from the cell-binding domain were cou-
pled covalently to plates, and their specific molar ac-
tivities in mediating BHK cell spreading were compared
with that of intact fibronectin. A 37-kD fragment puri-
fied from chymotryptic digests of human plasma fibro-
nectin had essentially the same specific molar activ-
ity as intact fibronectin. In contrast, other fragments
such as an 11.541) fragment lacking NHZ-terminal se-
quences of the 37-kD fragment had only poor spread-
ing activity on a molar basis. Furthermore, in com-
petitive inhibition assays of fibronectin-mediated cell
spreading, the 37-kD fragment was -325-fold more
active than the GRGDS synthetic peptide on a molar
basis. mAbs were produced using the 37-kD protein as
C
ELLULAR adhesion to specific extracellular matrix
components is required for a variety of biological
events including cell proliferation, embryonic de-
velopment, wound healing, and disease pathogenesis. The
adhesive glycoprotein fibronectin hasbeen anespecially im-
portant model system for deriving insights into the mecha-
nismsofcelladhesion and migration(8,9, 23, 36). Fibronec-
tin is a multifunctional glycoprotein with multiple binding
activities including those for heparin, collagen, fibrin, and
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an immunogen and their epitopes were characterized.
Two separate mAbs, one binding close to the RGD
site and the other to a site -15 kD distant from the
RGD site, individually inhibited BHK cell spreading
on fibronectin by >90%. In contrast, an antibody that
bound between these two sites had minimal inhibitory
activity. The antibodies found to be inhibitory in cell
spreading assays for BHK cells also inhibited both fibro-
nectin-mediated cell spreading and migration of human
HT1080 cells, functions which were also dependent
on function of the a5ß1 integrin (fibronectin receptor).
Assembly ofendogenously synthesized fibronectin into
an extracellular matrix was not significantly inhibited
by most of the anti-37-kD mAbs, but was strongly in-
hibited only by the antibodies binding close to the
RGD site or the putative synergy site. These results
indicate that a second site distant from the RGD site
on fibronectin is crucial for its full biological activity
in diverse functions dependent on the a5ßß fibronectin
receptor. This site is mapped by mAbs closer to the
RGD site than previously expected.
cell surface receptors. Thesebindingactivities are contained
in distinct, protease-resistant domains. The best character-
ized cell-binding domain of fibronectin occupies its central
region. This central cell-binding domain offibronectin me-
diates cell adhesion with a wide variety of cell types (1, 45,
46) through a (Gly)-Arg-Gly-Asp-(Ser) sequence. For ex-
ample, synthetic peptides containing this sequence block
fibronectin-mediated adhesion andbindingto cell surfacere-
ceptors (18, 39,40, 54). Moreover,direct deletion oftheArg-
Gly-Asp(RGD) sequencebysite-directedmutagenesiscauses
a loss of most cell adhesion activity (38).
AlthoughtheArg-Gly-Asp sequence is clearly ofgreatim-
portance as a cell adhesive signal, several major questions
remain. In vitro mutagenesis and analysis ofbacterially ex-
pressed fibronectin fusion proteins indicates that a secondmajor region ofthe protein is required for adhesive function
(4, 38). Studies comparing the biological activities of large
and small fibronectin fusion fragments and synthetic pep-
tides derived from fibronectin also indicate that most biolog-
ical activity is lost when short fibronectin fragments and pep-
tides are assayed even when the RGD sequence is retained
(2, 49) . Furthermore, the RGD sequence has been found in
several adhesive proteins that have distinct functions and
specificities and is also found in nonadhesive proteins (39,
45, 52). Consequently, further dissection of the molecular
mechanisms of action of fibronectin is required to elucidate
how a single molecule can mediate different types of adhe-
sion in different cell types, how the widely distributed RGD
peptide sequence can be used as part ofspecific receptor rec-
ognition systems, and how specific sequences in the mole-
cule are used in the more complex processes of cell migra-
tion and organization of fibronectin into a three-dimensional
fibrillar extracellular matrix (4, 8, 23, 33, 36, 53).
Our original finding of a putative synergistic site (38) that
mightprovide binding affinity and specificity to the fibronec-
tin RGD site has been clouded by several major uncertain-
ties. Because the synergy site was identified using only
amino-terminal deletion analysis, the final fusion proteins
might have had an incorrect conformation in the region of
the RGD recognition site due to the lack of a correct amino-
terminal sequence, thus, artifactually producing losses of ac-
tivity (see also ref. 27). Furthermore, no information was
available on which fibronectin receptor(s) could interact
with the synergy site and which types of processes involving
fibronectin require this "synergy" region, e.g., whether more
complex functions such as cell migration or fibronectin ma-
trix assembly require this site. Since the publication of the
work of Obara et al . (38), it has been reported that matrix
assembly may require both the a5ß, fibronectin receptor
and another, unidentified ß, integrin (13) .
A relatively direct, independent approach to answering
these questions is the development of specific mAbs that can
inhibit fibronectin function. If they can be mapped to differ-
ent points along the molecule, a series of inhibitory and
noninhibitory mAbs can provide insights into which sitesare
important for function in the form of an independent test of
the existence ofa second synergy site. They can also provide
tests of the role of this site in different biological processes.
In this study, we have characterized a "synergy" region in
the central cell-binding domain that is distinct from the RGD
site. Our approach has been to isolate and characterize the
shortest fully active fragment of fibronectin generated by
proteolysis. This protein fragment was then used as an im-
munogen to obtain mAbs clustered along this key region of
fibronectin. These mAbs have then been used in the im-
munological mapping of sites in fibronectin that are critical
for cell spreading and migration, as well as for assembly of
a fibrillar fibronectin matrix.
Materials andMethods
Purification ofFibronectin andFragments
Fibronectinwaspurified fromfresh-frozen citrated human plasma (National
Institutes of Health Blood Bank, Bethesda, MD) by gelatin-Sepharose
affinity chromatography and citric acid elution (35) . The 37-kD fragment
was generated by digesting 130 mg fibronectin in 90 ml 0.15 M NaCl, 10
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mM Tris-HCl, 0.02% sodium azide, pH 7.4, at 37°C for 20 h with 1.3 mg
chymotrypsin (Worthington Biochemicals, Freehold, NJ). The digestion
was terminated by adding PMSF to a final concentration of 1 mM. After
dialysis against 50 mM Tris-HCl, pH 7.4, the crude digest was applied to
a 27-ml bed volume gelatin-Sepharose affinity column. The flow-through
fractions were immediately applied to a 44-ml bed volume heparin-
Sepharose affinity column. Both affinity columns had been pre-equilibrated
with 50 mM Tris-HCI, pH 7.4. The flow-through fractions from the
heparin-Sepharose column were pooled and dialyzed against 3 mM sodium
phosphate, 0.02% sodium azide, pH 5.8, and appliedtoa preparative Mitsui
Toatsu HCA hydroxyapatite HPLC column (Rainin, Woburn, MA). The
columnwas eluted with a lineargradient of3 to 120 mM sodiumphosphate,
pH 5.8, using anFPLC system (Pharmacia LKB Biotechnology, Piscataway,
NJ). The material eluting between 95 and 115 mM sodium phosphate was
pooled, dialyzed against 1 mM sodium phosphate, pH 6.8, andconcentrated
by applying to a 2-ml Bio-gel HTP hydroxyapatite column(BioRad Labora-
tories, Richmond, CA), eluting with 200 mM sodium phosphate, pH 6.8.
The eluted material was further concentrated using a Centricon-10
microconcentrator (Amicon Corp., Danvers, MA), and applied to a Su-
perose 12 column (Pharmacia LKB) and eluted with PBS+ . Column frac-
tions containing protein as judged by absorbance at 280 nm were analyzed
by gel electrophoresis and Western blotting using mAb 333, which binds
to fibronectin near the RGD site (2).
The 11.5-kD cell-binding fibronectin fragment was prepared asdescribed
using a mAb 333 affinity column (2). Gly-Arg-Gly-Asp-Ser (GRGDS) syn-
thetic peptide was custom synthesized by Immuno-Dynamics, Inc. (La
Jolla, CA) and was further purified by reversed phase HPLC and Dowex
chromatography before use.
NHS-terminaland COOH-terminalAmino
Acid Sequencing
Purified 37-kD fragment was precipitated with ethanol, washed several
times with absolute ethanol, dried by SpeedVac (Savant Instruments, Inc.,
Hicksville, NY), redissolved in 50% acetic acid, and analyzed by auto-
mated gas phase sequencing (Applied Biosystems, Foster City CA). This
amino acid sequence analysis was performed in the Protein Analysis Labo-
ratory of the Cancer Center of Wake Forest University supported in part
by NIH grants CA-12197, RR-04869, and a grant from the North Carolina
Biotechnology Center. To identify COON-terminal amino acids, 1.5 nmol
of purified 37-kD fragment in 100 Eel 0.1 M pyridine-acetate-collidine
buffer, pH 8.3, was digested by carboxypeptidase A (type 1-DFP; Sigma
Chemical Co., St. Louis, MO) for 20 h at 37°C at a 5 :1 molar ratio. The
reaction was terminated with 50 Eel acetic acid, and the solution was dried
by SpeedVac and resolubilized in 100 Al 0.2 M citric acid (pH 2.2). Liber-
ated amino acids were analyzed by HPLC using an AA-Pak column (Japan
Spectroscopic Co., Ltd., Tokyo) with post-column o-phthalaldehyde de-
rivatization (with the help of Dr. Masafumi Kamada, Department of Bio-
chemistry Science University of Tokyo), and quantitated using external
amino acid standards. Controls were carboxypeptidase incubation without
sample, and substitution of met-enkephalin (Tyr-Gly-Gly-Phe-Met) as a
positive control .
BiologicalAssays
Cell spreading assays were performed in 96-well microtiter plates using
fibroblastic BHK cells as described previously (54). Substrates were pre-
pared either by coating tissue culture plates (Costar Laboratories) with so-
lutions of fibronectin or fragments as described (54) or by covalently cou-
pling fibronectin or its fragments to CovaLink plates (Nunc, Naperville,
IL). To prepare covalently coupled substrates, triplicate CovaLink wells
were treated with 100 Eelof 1 mg/ml bis(sulfo-succini*nidyl) suberate cross-
linking reagent (BS3;' Pierce Chemical Co., Rockf)rd, IL) in PBS+ for
30 min at 4°C. After washing, the wells were incubated with 100,ul ofvari-
ous concentrations of fibronectin or fragments for 1 h at room temperature.
Background spreading was minimized by first incubating the wells with
0.15 M glycine for 30 min, followed by a 30-min incubation with 1% heat-
denatured BSA, prepared as described (54). The plates were extensively
washed with PBS+ before use. One well of each triplicate set was used to
assay cell spreading activity. The remaining twowells ofeachset were used
to quantitate amounts of each protein covalently coupled in the wells by
ELISA using 5 Ag/mlmAb 333 as the first antibody inPBS+ supplemented
with 0.15 M glycine and 0.1% BSA.
1. Abbreviation used in this paper: BS3, bis(sulfosuccinimidyl) suberate.
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viously (3,50) . Fibronectin matrix assemblyassays using WI-38 humanem-
bryonic lung fibroblasts were carried out as described (3). Fibronectin ma-
trices stained with FITC-labeled antihuman fibronectin antibodies were
photographed using identical exposure times for all treatment conditions
with Kodak Tri-X film in a Zeiss Photomicroscope III using a 63x, 1 .4 NA
objective. Matrix assembly was quantitated by counting the numbers of
fibrils observed to be crossing a straight line ofarbitrary fixed length (100
,um on each field) drawn across randomly selected microscope fields .
ELISA
TheELISAs were carried out by incubating protein coated wells of either
Immunobn-1, Costar, or CovaLink microtiter plates with 100 Al of either
hybridoma-conditioned medium or purified antifibronectinmAbs in 0.5%
Tween-20 in PBS (incubation buffer) for 2 h at room temperature followed
by washing with incubation buffer. In experiments where Immulon-1 or
Costar plates were used, HRP-conjugated, affinity purified anti-rat IgG
(ICN Immunobiologicals, Costa Mesa,CA) at a 1:200 dilution in incuba-
tion buffer was used as the secondary antibody. After washing, peroxidase
substrate in the form of 2 mM 2,2'-azino-bis(3-ethylbenzthiazoline-6-
sulfonic acid) (ABTS), 2.5 mM H202 in 0.1 M sodium acetate, 0.05 M
NaH2P04, 0.01% thimerosal was added and reaction product was quanti-
tated at 405 nm. When CovaLink plates were used, the secondary antibody
was biotin-labeled anti-rat IgG (ICN Inununobiologicals) diluted 1/300 in
incubation buffer. The wells were washed again with incubation buffer and
100 lul of a 1/200 dilution of HRP-conjugated avidin (ICN Immunobiologi-
cals) was added for 1 h, followed by further washing and addition ofperoxi-
dase substrate .
Production andCharacterization ofmAbs against
the 37-kDFragment
Hybridomas secreting anti-37-kD fragment mAbs were produced by the fu-
sion ofY3 rat myeloma cells with spleen cells from aSprague-Dawley rat
as described (15) . The rat had been previously immunized with highly
purified 37-kD fragmentby intraperitoneal injection withcomplete Freund's
adjuvant and boosted with the 37-kD fragment in incomplete Freund's adju-
vant . Positive clones wereidentified by ELISA using 1001ul hybridoma con-
ditioned medium as the first antibody. ELISA substrates were prepared by
incubating 5 lug/ml 37-kD fragment with 96-well Costar tissue culture
clusters and then blocking with 0.1% crystallineBSA . The positive hybrid-
omas were subcloned twice by limiting dilution and isotyped using a Rat
MonoAb-ID/SP kit (Zymed Laboratories, Inc., San Francisco, CA). For the
large-scale production of antibodies, the hybridomas were cultured in
serum-free medium supplemented with BSA and ITS Premix (Collaborative
Research, Bedford, MA) as described (2) . mAbs were purified from
hybridoma-conditioned serum-free medium by protein G affinity chroma-
tography (Pierce Chemical Co .) . All hybridomas selected for further ex-
perimentation were subcloned at least twice by limiting dilution .
Epitope mapping of mAbs was carried out by ELISA using fusion pro-
teins expressed by the Xgtll system inE . coli based on recombinantDNA
mutagenesis of fibronectin (38; footnote 2) . After affinity purificationusing
mAb 333-Sepharose columns (38), the fusion proteins or fibronectin frag-
ments were coated onto Immulon-1 plates (Dynatech Laboratories, Inc.,
Chantilly, VA) at 5-10 lug/ml in PBS+ for 1 h at room temperature, then
subjected to ELISA usually using purified IgG at 50 ug/ml or, in some
cases, hybridoma-conditioned medium containing 40 to 50 lug/ml IgG.
mAb binding competition assays were carried out as described above for
the standard ELISAs using fibronectin-coated Costar 96-well plates. The
wells were preincubated with one of each of the unlabeled mAbs for 1 h .
Then mAbs that had been directly labeled with HRP were added for 1 h .
After extensive washing, binding of labeled mAb was quantitated as de-
scribed for the standard ELISA. Purified mAbs were labeled directly with
HRP using preactivated peroxidase in the form of ActiZyme-HRP (Zymed
Laboratories, Inc.) according to the manufacturer's instructions. Affinity
constants ofmAb binding to fibronectin were determined by radioimmuno-
assay using the procedure of Frankel and Gerhard (14) .
OtherMethods
Protein concentrations were determined by theBCA protein assay (Pierce
Chemical Co.) usingBSA as a standard . SDS-PAGE was performed as de-
scribed (29), using a4% stacking gel and 10% resolving gel . Proteins were
transferred to nitrocellulose membrane (Schleicher& Schuell, Keene NH)
as described (7) . Protein bands were localized either by staining with 2%
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Amido Black IOB or with mAb 333 . Blots used for mAb detection of
fibronectin fragments were blocked for 30 min with 5% nonfat dry milk
solids in PBS+, and intmunostaining was carried out using mAb 333 and
HRP-conjugated, affinity-purified rabbit anti-rat IgG (ICN Immunobio-
logicals) as first and second antibodies, respectively . HRP activity was
localized using 5 mg/ml 3,3'-diaminobenzidine, 0.01% H202 in 0.1 M
Tris-HCI, pH 7.4 .
Results
PurificationandCharacterization of
a 37-kD Cell-bindingFragment
Previous reports have described proteolytic cell-binding
fragmentsderivedfrom thecentralportion of fibronectin and
containing the Arg-GlyAsp cell recognition site ranging in
size from 11.5 up to 120 kD (2, 19, 41, 17a, 46, 47, 57) .
Whereas the larger fragments bind to cells with similar
affinities as the intact molecule, the small 11 .5-kD fragment
hasbeen foundto bind to cellswith amarkedly lower affinity
(2) . We have usedapartial chymotrypsin digestionfollowed
by chromatographic methods to generate a fibronectin cell-
binding fragment that would be of an intermediate size be-
tween those of the fully active 75-kD fragment and the low
affinity 11.5-kD fragment . As shown in Fig. 1 (lane 2), aho-
mogenous fragment with an estimated size of37kD was ob-
tained after purification . This fragment was recognized by
mAb 333, which binds to the previously described 11.5-kD
cell-binding fragment and inhibits cell attachment to the
Arg-GlyAsp site (2,21) .
Thesequence of the first 20 amino acidsofthe 37-kDfrag-
ment was foundto be Thr-Val-Lys-Asp-Asp-Lys-Glu-Ser-Val-
Pro-Ile-Ser-Asp-Thr-Ile-Ile-Pro-AlaVal-Pro (TVKDDKES-
VPISDTIIPAVP), in complete agreement with the known
humanfibronectin sequence as deducedfromcDNA analysis
starting at residue 1218andlacking theED-13(EDb or EIIlb)
sequence (28,36) . Analysis of the first few amino acid res-
idues was entirely unambiguous, suggesting that the 37-kD
fragment had been purified to homogeneity as indicated by
the electrophoretic analysis in Fig. 1. The amino-terminal
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Figure 1. Western blot anal-
ysis of chymotryptic digest of
fibronectin and purified 37-kD
cell-binding fragment . Frag-
ments generated by treating
humanplasma fibronectinwith
chymotrypsin (lanes 1 and 3)
or purified 37ÁD fragment
(lanes 2 and4) were resolved
by electrophoresis on a 10%
polyacrylamide gelunder non-
reducing conditions followed
by electroblotting to nitrocel-
lulose. Fragments were stained
with either amidoblack (lanes
1 and 2) ormAb 333 (which
binds close to theRGD site of
fibronectin) and HRP-labeled
anti-rat IgG serum (lanes 3
and 4) . The relative positions
ofmolecularweight standards
are indicated on the left .sequence of this 37-kD fragment exactly matched that of a
34-kD fragment from bovine fibronectin isolated by Skor-
stengaard et al, (47) after extensive digestion with chymo-
trypsin. Analysis of carboxy-terminal amino acids by car-
boxypeptidase A treatment and amino acid analysis yielded
214 pmol Met and 174 pmol Gln from an initial 300 pmol
of 37-kD fragment, indicating that the 37-kD human frag-
ment has the same carboxy-terminal Gln-Met sequence as
the bovine fragment (47). This fragment therefore starts
at residue 1218 (Thr,2,8), lacks the ED-B domain, and ter-
minates at the methionine at residue 1517 (using the pub-
lished nomenclature omitting the ED-B sequence: refs. 28
and 47)2.
BiologicalActivityofthe 37-kDFragment
The ability of solubilized 37-kD fragment to inhibit BHK
fibroblastic cell spreading on fibronectin substrates was
compared to that of the 11.5-kD fragment and synthetic
GRGDS peptide. As shown in Fig. 2, the 37-kD fragment,
the 11.5-kD fragment, and GRGDS peptide could all inhibit
cell spreading on fibronectin with half-maximal inhibition
occurring at concentrations of 47 ug/ml (1.2 x 10-6 M),
850 pg/ml (74 x 10-6 M) and 190 p,g/ml (390 x 10-6 M),
respectively. Thus, on a molar basis, the 37-kD fragment was
m
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Figure 2. Comparisonofthe relative inhibitory activities of the 37-
and 11.5kD cell-binding fragments and GRGDS synthetic peptide
on spreading of BHK fibroblasts. BHK cells were incubated in 96-
well tissue culture clusters coated with 2 p,g/ml fibronectin in the
presence of the indicated concentrations of 37-kD fibronectin cell-
binding fragment (e), 11.5-kD fibronectin cell-binding fragment
(o), or GRGDS peptide (v). The open circle indicates the percent
cells spread in control wells containing no inhibitor. Each point in-
dicatesthe average percentage ofcells spread from 10 random fields
(100 cells counted/field) f SEM.
2. Usingterminology basedon the presently known full sequence (22, 36),
the carboxy-terminal residue ofthe 37-kD fragment is Met,60s. This frag-
ment contains the terminal 17 amino acids of the fibronectin repeating unit
III-7, the entirety ofIII-9, III-10, and III-11, and eightamino acids ofIII-12.
Its theoretical molecular size fromthe sequence of human plasma fibronec-
tin in the absence of posuranslational modification would be 33 kD (28).
For comparison, the 11.5-kD fragment extends from Ile,50, to the same
Met,6os in the currrent full sequence nomenclature (36, 39, 41), and it con-
sists primarily of unit III-11 (with the carboxy-terminal end of III-10 and
the amino-terminal end of III-12).
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325-fold more active than the GRGDS peptide and 60-fold
more active than the 11.5-kD fragment-in-this assay. These
results indicate that information present in the 37-kD frag-
ment, but lacking from the 11.5-kD fragment and synthetic
peptide, is important for biological activity.
To compare directly the relative cell spreading activities
of fibronectin and fragments, substrates were prepared by
covalently coupling either intact fibronectin, the 37-kD frag-
ment, or the 11.5-kD fragment to CovaLink activated polysty-
rene 96-well assay plates, and the relative amounts of each
protein were measured by ELISA using duplicate parallel
wells as described in Materials and Methods. The data,
shown in Fig. 3, were plotted as the percentage of spread
cells as a function of the relative amount of moles of
fibronectin or fragment actually present on the substrate.
This experiment showed that the 37-kD fragment had essen-
tially the same cell spreading activity as fibronectin itself on
a molar basis. The activity of the 11.5-kD fragment was very
low, suggesting that the 11.5-kD fragment lacks information
contained in the 37-kD fragment required for complete inter-
action with fibroblastic cells.
CharacterizationofmAbsRaised Against
the37-kD Fragment
Five hybridoma clones designated 11E5, 3B8, 13G12, 12B4,
and 16G3 were selected for use in this study. All of these hy-
bridoma clones secreted antibodies of the IgG, subclass.
The epitope of each mAb was analyzed by ELISA using a
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Figure 3. Spreading of BHK cells on substratesprepared by cova-
lently cross-linking fibronectin or cell-binding fragments to plastic.
Fibronectin (o), 37-kD (9), or 11.5-kD (m) cell-binding fragments
at various concentrations ranging from 0.03 to 4.0 ttg/ml were cou-
pledtoNunc Covalinkwellsusing BS3 homobifunctional cross-link-
ing reagent and were assayed for BHK cell-spreading activity. Each
point indicates the average percentage ofcells spread from 10 ran-
dom fields (100 cells counted/field) f SEM. The relative amount
ofeach protein presentin the wellsas measured by theELISA meth-
od on parallel duplicate wells is indicated on the abscissa in units
of absorbance at 405 nm.Table L Epitope Mapping by ELISA
The epitopes for each ofthe mAbs generated in this study and for the previous-
ly described mAb 333 were mapped on the 37-kD fibronectin cell-binding
fragment by ELISA using a variety of deletion mutants in the form of 0-gal-
actosidase fusion proteins expressed in the Xgtll bacterial expression system
(38; footnote 2). The values in the table indicate the last amino acid residue
present at the boundaries of the fibronectin sequence deletions from the amino
terminus. For example, mAb 11E5 showed positive ELISAs for deletions ex-
tending up to (but not ncluding) residue 1234, but this mAb was negative for
binding to adjacent deletion mutants, the closest of which retained residue
1260. The binding site for mAb 16G3 was the most carboxyl terminal. The epi-
tope formAb 11E5 was also mapped for its carboxyl-terminal boundary, which
was residue 1329 . All residue numbers are based on the numbering system for
fibronectin of entry FNHU, accession number A03213, in the NBRF PIR (Pro-
tein Identification Resource) databank, which omits the ED-B (EIIIB) alterna-
tively spliced domain and matches the notation of previous mutants (38).
Another method of mapping is based on numbering the 17 known type III
repeats of fibronectin consecutively (ED-B would be numbered III-8 according
to the nomenclature of ref. 36, p. 4). Although further mapping is needed to
determine exact epitope boundaries, mAb I IE5 appears to bind to III-9; 3138,
3G12, and 12B4 bind to portions ofIII-10and possibly III-11 ; 16G3 recognizes
III-11; and 333 binds III-10 and/or III-11 .
series of fibronectin fragments and bacterially expressed
fibronectin fusion proteins. All mAbs bound to intact fibro-
nectin, the 37-kD fragment, and the clone 6 fusion protein
which overlaps the entire sequence of 37-kD fragment (38) .
Only mAb 16G3 and the control mAb 333 bound to the 11.5-
kD fragment, indicating that the epitopes of mAb 333 and
mAb 16G3 are both located nearthe carboxy-terminal region
ofthe 37-kD sequence, close to the RGD site. mAb I IE5 did
not bind to clone 18 which overlaps all of the 37-kD fragment
except the amino-terminal region (38), indicating that the
epitope of this mAb was located in the most amino-terminal
region. Further analyses were carried out using a series
of fibronectin fusion proteins with known deletions. Thus,
the epitope of mAb 11E5 was mapped -11 kD from the
amino terminus of the 37-kD fragment, those for mAbs 3B8,
13G12, and 12B4 are in sequence from the amino to the car-
boxy terminus, and the epitope for mAb 16G3 is closer to
the Arg-Gly-Asp site than mAb 333 (Table 1).
Table II. Mutual Competition Binding Profiles of Anti-374D mAbs by ELISA
Competitive inhibition ofbinding between HRP-labeled mAbs and nonlabeled mAbs in all combinations was tested by ELISA. Aliquots of fibronectin coated onto
Costar plates at a concentration of5 pg/ml solution were preincubated with each ofthe nonlabeled mAbs (100 pl at 50,ug/ml) for 3 h at room temperature. Subse-
quently, 10 pl of HRP-labeled mAb (50 pg/ml) was added to each well and the antibodies were coincubated for 1 h at room temperature (nonlabeled mAb/labeled
mAb = 10:1). After washing, the activity of the HRP on the labeled mAbs bound to fibronectin was measured. Data were expressed as percentage of total absor-
bance observed without nonlabeled mAb (noncompeted control) for each mAb, which were as follows: IIE5, 1.86 f 0.05 absorbance units; 3138, 2.22 f 0.12;
13G12, 1 .99 t 0.03; 12134, 1 .62 t 0.01 ; and 16G3, 1.98 t 0.06. All values represent the mean t SEM of four assays.
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All ofthe mAbs were furthertested by ELISA for competi-
tive inhibition ofbinding to fibronectinbetween HRP labeled
coupled mAbs and nonlabeled mAbs (Table II) . Each unla-
beled mAb completely inhibited binding of its HRP-labeled
counterpart. mAbs 13B12 and 12B4 were found to compete
for similar binding sites. No other pair of mAbs was found
to compete for binding. These results indicate that the five
mAbs recognize four distinct epitopes. The results ofthe epi-
tope mapping experiments are summarized in Fig. 4 (top).
Immunological MappingofTwo SeparateRegions
RequiredforCellAdhesion
The biological activitiesof each mAb were examined in three
different assays to evaluate fibronectin functions in cell
spreading, cell migration, and matrix assembly. As shown in
Fig. 4 (bottom), mAbs 3B8 and 16G3 were both found to in-
hibit BHK cell spreading, requiring only -10 lAg/ml for half-
maximal inhibition. Similarly, half-maximal inhibition of
HT1080 fibrosarcoma cell spreading was also obtained with
mAbs 3B8 and 16G3 at -10 ftg/ml. These two mAbs also
inhibited BHK cell spreading on the 37-kD fragment itself,
whereas even 100 ltg/ml of each did not affect spreading on
5 Ag/ml vitronectin (data not shown) . In contrast to the in-
hibitory activity of mAbs 3B8 and 16G3 on fibronectin,
mAbs I IE5, 13G12, and 12B4 had minimal inhibitory activ-
ity in this assay, even at concentrations of 100 Ag/ml (Fig.
4). The inhibitory activity of mAb 16G3 can be explained
by the proximity ofits epitope to the Arg-Gly-Asp site. How-
ever, the inhibition by the mAb 3B8 can only be easily ex-
plained by its blocking of a second cell adhesion site within
the 37-kD fragment. It is important to note that in this ex-
periment, mAb 13G12 (and to a lesser extent 12B4), which
bound to sites on the 37-kD fragment between those for the
two inhibitory mAbs, can be considered negative controls
that rule out possible steric effects of the inhibitory antibod-
ies and that demonstrate separability of the two sites.
One possible trivial explanation of the cell spreading data
is that the inhibitory mAbs bound to fibronectin with high
affinity and the noninhibitory mAbs bound with low affinity.
To rule out this possibility, the binding constant of each mAb
for fibronectin was determined by radioimmunoassay. The
inhibitory mAbs 3B8 and 16G3 were found to have esti-
mated Kd values for fibronectin coated onto the plastic sub-
strate of 1.3 x 10- 9 and 1.0 x 10- 9 M, respectively. The
noninhibitory antibodies I IE5, 13G12, and 12B4 were found
mAb Positive
Residue number
Negative
IIE5 1217 1260
3B8 1355 1359
13G12 1359 1363
12B4 1363 1368
333 1384 1429
16G3 1429 -
Nonlabeled mAbs IIE5 3138
Labeled mAbs
13G12 12B4 16G3
IIE5 2t1 83t7 101 t 2 98 t 2 105 t 7
3B8 110t6 1 t0 107 t 1 113 t 4 91 f 1
13G12 88f7 103t5 1 t 1 1 t 0 115 f 12
12B4 91 t7 97t6 2 f 0 1 t 1 103 f 8
16G3 116 5 105 t 9 108 f2 120t5 1 t 1m
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to have estimated Kd values of 1.2 x 10-9, 1.2 x 10-'0, and
1.6 x 10-'0 M, respectively. Thus, differences in the appar-
ent affinity of the mAbs cannot account for the observed
differences in biological activity, and the simplest interpreta-
tion of the data is that mAb 3B8 inhibits cell spreading
by binding to a second, crucial cell-binding site -15 kD
distant from the RGD site in the NH2-terminal direction on
fibronectin.
Immunological MappingofSites Required
forCellMigration
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Monoclonal Antibody Concentration (pg/ml)
Besides mediating adhesion, fibronectin can also promote
migration by a variety of cell types. Fig. 5 shows that mAbs
3B8 and 16G3 at 200 pg/ml strongly inhibited cell migration
by HT-1080 cells on fibronectin (72 and 84% inhibition,
respectively; both values were statistically significant at the
p < 0.001 level); half-maximal inhibition was observed at N2
pg/ml of each of these two antibodies (data not shown). The
inhibition of migration in this outgrowth assay was con-
firmed by time-lapse video microscopy: both mAb 3B8 and
mAb 16G3 strongly inhibited the migration of HT-1080 cells
as determined by following the paths of individual cells,
whether they existed as single cells or as aggregates of cells
in contact; although cells treated with these two mAbs re-
mained attached to the fibronectin substrate, they moved
back-and-forth randomly in place rather than undergoing
directed translocation (data not shown). In outgrowth assays
conducted in parallel to these anti-37-kD experiments, simi-
larly high levels of inhibition of migration (75-100%) were
obtained with mAb 16, a mAb that specifically inhibits func-
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Figure 4. Biological activities
and map ofthe epitopes of the
anti-37-kD mAbs. (top) The
estimated epitope recognition
site of each mAb as mapped
by ELISA analysis of fusion
proteins and fragments is in-
dicated along the 37-kD se-
quence; see Table I for numer-
ical mapping data. The solid
arrows indicate the active
mAbs and the open arrows in-
dicate the inactive mAbs as
determined by cell spreading
assays. (Bottom) Inhibition of
BHK cell spreading by each of
theanti-37-kD fragment mAbs
on fibronectin substrates. Tis-
sue culture clusters coated with
2 14g/ml fibronectin were pre-
treated for 60 min with 50 tcl
of the various mAbs. Then 25
pl of BHK cell suspension
containing 1 x 104 cells were
--------
￿
added to the wellsto yield the
indicated final concentrations
of mAbs. Each bar represents
the average of ten determina-
tions from random fields (100
cells/field) of duplicate wells
t SEM.
tion of the a5ß1 fibronectin receptor in cell migration by
this particular cell on fibronectin (data not shown ; see also
refs. 3 and 55) .
In contrast, mAb 13G12 did not significantly inhibit
migration (Fig. 5), even though the epitope for this mAb lies
between those of the two highly active mAbs. mAb 12B4
reproducibly showed substantial but not complete inhibitory
activity in these cell migration assays (60% inhibition,
significant at the p < 0.001 level). Although minimal in-
hibitory activity was observed for this particular mAb in the
BHK cell spreading assay for cell adhesion (see Fig. 4),
significant activity was also foundin parallel spreading assay
conducted with the HT1080 cells used for the cell migration
assays (50% inhibition ; Fig. 6).
Immunological MappingofSites Required
forFibronectin Matrix Assembly
Regions of the central cell-binding domain of fibronectin
molecule required for its assembly into a fibrillar matrix
were mapped by incubating human WI-38 fibroblasts with
each mAb during the process of matrix assembly over a
period of 24 h. As shown in Fig. 7, mAb 3B8 that binds to
the putative synergy region inhibited strongly, and mAb
16G3 that binds close to the RGD site was also inhibitory,
whereas the three other mAbs had little or no effect on this
process. Direct quantitation of fibrillogenesis as shown in
Fig. 8 showed that mAb 3B8 inhibited fibril formation by
75 %, while mAb 16G3 inhibited by 63% at 200 pg/ml
(p < 0.001 for both antibodies) . Half-maximal inhibition of
fibrillogenesis occurred at -20 pg/ml for mAb 3B8 and at
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40 jg/ml formAb 16G3 ; similar patterns of inhibition were
observed using a previously described immunoblotting pro-
tocol (3 ; data not shown) . mAb 333, which also binds close
to the RGD site (though not as closely as mAb 16G3), also
inhibited matrix assembly by 73% (Fig . 8) . There were only
minimal amounts of inhibitionby control mAbs that did not
reach statistically significant levels, including by the mAbs
located between the two active sites : mAb 13G12 showed 8
inhibition (p = 0.5), andmAb 12B4 showed only 15% inhi-
bition (p = 0.3) in comparison with the untreated control
(Fig. 8) . As reported previously (3), mAb 16 and mAb 13
against the a and ß subunits of the a5ß, fibronectin receptor
also inhibited fibrillogenesis in this newer assay (Fig . 8 ; 75
inhibition) . mAb 13 was the most effective of allmAb inhibi-
tors in this assay, inhibiting fibril formation by 86% (Fig. 8) .
These levels of inhibition can be compared with the 75% in-
hibition by3B8. Interestingly, the maximal concentrations of
the anti-a4 fibronectin receptor antibody and the antifibro-
nectin synergy region antibody resulted in similar levels of
inhibition (both inhibited 75 t 5%), whereas the anti-ß,
antibody mAb 13 showed additional inhibition (86 f 4%) .
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Figure5 . Inhibition ofHT1080 fibrosarcoma cell migrationby anti-
37-kD mAbs . (top) Outward migration of cells from 1 A1 agarose
droplets containing 3 x 104 cells onto a substrate coated with
5 Ag/ml human plasma fibronectin in the presence of (a) mAb
IlE5, (b) mAb 3B8, (c) mAb 13G12, (d)mAb 12B4, and (e)mAb
16G3. (bottom) Outward migration of cells from 1 t1 agarose
droplets containing 3 x 104 cells onto a substrate coated with
5 ug/ml human plasma fibronectin was quantitated and expressed
as the net area occupied by migrating cells after culturing for 3 d
in the presence of 200 jg/ml of the mAbs indicated along the ab-
scissa or with no antibody in the control samples . mAb 13H7 was
a control rat mAb. Bars indicate the average of three samples t
SEM . Bar, 1 mm .
Discussion
We have purified and characterized a 37-kD fragment of
fibronectin that was found to retain cell adhesive activity
similar to that of intact fibronectin . This human fibronectin
fragment corresponds in structure to a protease-resistant
fragment of bovine fibronectin sequenced by Skorstengaard
et al . (47) containing the 9th through 11th type III repeats of
fibronectin . Its resistance to proteolysis suggests that it pos-
sesses considerable structure, rather than existing as a linear
polypeptide . Using this fragment as an immunogen, we have
generated a panel ofmAbs that bind to four distinct epitopes
found in the 37-kD fragment . Applying these antibodies as
functional probes, we find that two distinct regions of the
central cell-binding domain are important for fibronectin-
mediated cell spreading and migration, and also for the as-
sembly of extracellular fibronectin fibrils . One region ap-
pears to involve the Arg-Gly-Asp site . The second region
maps a substantial distance away from the RGD site, to a lo-
cation estimated to be <15 kD of polypeptide sequence to-
ward the amino terminus . This site, which is inhibited by
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Figure 6. Inhibition ofHT1080 fibrosarcoma cell spreading by anti-
37-kDmAbs. Tissue culture clusters (96-well) coated with 5 Wg/ml
fibronectin were pretreated for 60 min with 50 pl of the various
mAbs. Then 25 gl of HT-1080 cell suspension containing 1 x 10°
cells were added to the wells to yield a final concentration of200
ig/ml of each mAb. mAb 13117 was a control rat mAb. Each bar
represents the average of ten determinations from random fields
(100 cells/field) t SEM .
mAb 3B8, is flanked by epitopes to which other mAbs bind
with high affinity, yet binding to these flanking sites is not
inhibitory. For example, mAb binding to an epitope esti-
mated to be >25 kD of polypeptide sequence away from
RGD is not inhibitory, and an epitope with a boundary >14
kD away from RGD is also not inhibitory in various biologi-
cal assays.
These distances can be compared with rougher estimates
from previous studies based on adhesive activity of several
truncation mutants of fibronectin expressed in bacteria (38)
or on partially inhibitory activities of mAbs (26). Our previ-
ous study showed a loss of activity after truncation of fibro-
nectin sequences >20 kD away (38). The mAb studymapped
a partially active site 153-229 amino acid residues (17-25
kD) upstream from the RGD site (26) . The finer mapping
possible in the present study suggests that a particularly im-
portant region is located -14-15 kD away from the RGD
site, rather than the original rough estimates a greater dis-
tance away. This new estimate is of interest in that it moves
the mapped site of this postulated second, synergy region
away from the location of the alternatively spliced ED-B
(EHIA) site, reducing the likelihood that alternative splicing
could directly affect the biological function of this region.
Recent fine-structure mapping ofthe putative synergistic re-
gion by site-directed mutagenesis has confirmed that a major
functional subregion corresponds to the binding site of n1Ab
3B8 (4a). A second, quantitatively less important subregion
was mapped further toward the amino terminus (4a), corre-
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sponding to the originally described site of loss of activity
(38) and possibly to the binding site of the partially active
mAb described by Katayama et al. (26).
The 37-kD proteolytic fragment we describe is half the
size of the smallest fragment previously reported to retain
full biological activity (19). As such, it directly confirms the
prediction from mutagenesis studies that at least 52% of the
amino-terminal sequence of fibronectin is not necessary for
cell adhesion. The sequences in fibronectin required for cell
migration require further characterization. The Arg-Gly-
Asp sequence of fibronectin and other molecules is thought
to be required for the migration of certain embryonic and
adult cellsbased on competitive inhibition studies (6, 10, 30,
48). More extensive studies of neural crest derivatives reveal
complex requirements for sites besides the RGD sequence;
these cells might use the CS1 alternatively spliced sequence,
the synergy region, and other sequences in fibronectin for
migration or neurite extension .(11, 21, 31, 37) .
In this study, we examined cell migration in a system
where the requirements formigration were simpler. HT1080
cellswere chosen because oftheir markeddependence on the
a5ß, fibronectin receptor for migration (55) . Under our
present assay conditions, an antibody against either the a5
or ß, subunits blocks migration. Conversely, antibodies
against either subunit can substitute for the ligand and serve
as substrates for migration (55) . Using this cell line, we find
by antifibronectin mAb analysis that both the synergy region
and the RGD region are important for migration mediated
by this particular receptor. A mAb that binds to fibronectin
between these regions with high affinity (mAb 13G12) is not
inhibitory. Consistent with the results, preliminary binding
studies indicate that 3B8, the mAb that binds to the synergy
region, inhibits the binding of a5ß, to a fibronectin cell-
binding domain affinity column.
Extracellular matrix assembly is a complex process thought
to be dependent on integrin receptors and on both an amino-
terminal 70-kD domain and the central cell-binding domain
of fibronectin (34, 36). Antibodies against the a subunit of
the classical fibronectin receptor 01501 partially inhibit fibro-
nectin matrix assembly (3), and transfection of this receptor
into CHO cells substantially promotes matrix assembly (16).
Nevertheless, at least one other ß, integrin appears to be
involved in matrix assembly, since full inhibition is obtained
only by blocking the functions of all ß, integrins (13). Our
present results indicate that important sites are located in
both the RGD region and the synergy region of fibronectin.
mAbs against either ofthese sitesstrongly inhibit fibronectin
matrix assembly. Interestingly, none of the antifibronectin
mAbs alone inhibited matrix assembly to the same degree
as the antiintegrin ß, mAb, consistent with earlier findings
that interactions of fibronectin with multiple ß, integrins
are required for proper fibril formation (13, 42).
A number of integrin receptors have been reported to bind
to fibronectin, including a,ß,, a5ß,, a.ß3, and avß,. Direct
binding to the RGD motif is thought to explain the function
of many of these fibronectin receptors (4, 5, 8, 12, 17, 20,
22, 23, 25, 36). It is interesting to compare the requirements
for different receptors for differing cellular functions involv-
ing fibronectin; initial cell attachmentto fibronectin often in-
volves the classical c«sßi receptor. Cell spreading on fibro-
nectin can require this receptor (55) or proceed quite well
1302Figure 7 . Inhibition of fibronectin extracellular matrix assembly by anti-37-kD mAbs. WI-38 human lung fibroblasts were cultured for
24 h with or withoutthe indicated mAbs at 200 ug/ml, then fixed, permeabilized, and stained with FITC-labeled rabbit antihuman fibronec-
tin antibody as described previously (3) . These immunofluorescence micrographs were taken and printed using identical exposure times
to permit direct comparisons . (a) Untreated control ; (b)mAb 11E5 ; (c) mAb 3138 ; (d) untreated control ; (e) mAb 13G12 ; (f)mAb 12134 ;
(g) mAb 16G3 ; (h) control rat mAb 13H7. Bar, 20 Am .
Monoclonal Antibodies
Of
Figure 8. Quantitation ofthe inhibition of fibronectin matrixassem-
bly by mAbs . WI-38 fibroblasts were cultured for 24 h in the pres-
ence of 200 lzg/ml of the indicated mAbs, and then stained with
FM-labeled antifibronectin antibody. Fibrils observed to cross a
line of fixed length in random microscopic fields were counted for
each experimental condition . Bars indicate the average of data from
10 random fields for each condition showing numbers of fibrils per
1001em f SEM .
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in other cells such asWI-38 fibroblasts even if it is inhibited
(4) . Migration on fibronectin can be inhibited by antibodies
to this receptor inHT1080 cells and others, yetWI-38 fibro-
blasts show no inhibition or even an augmentation of migra-
tion rates . Fibronectin matrix assembly is partially depen-
dent on a5ß,, yetmay also require other ß, integrins (4, 13,
16,42) .
This complex picture is further complicated by the ques-
tion of whether more than theRGD site is needed for various
functions . Mutagenesis studies have implicated a second,
synergistic site in cell adhesion to fibronectin by BHK cells
(27, 38) . Such studies are undermined by concerns about the
effects of mutations on polypeptide conformation, which
may help to explain the discrepancies between these investi-
gations (compare refs. 27, 38, and footnote 2) . This study
provides independent, immunological evidence for the role
of a second region in the central cell-binding domain of
fibronectin that is involved not only in cell adhesion, but in
at least two other major functions ofthe protein . The fact that
this epitope located distant from the RGD site, but not one
or two intervening epitopes, is implicated in three different
processes involving cell interactions with fibronectin indi-
cates that this region is a functional site that either binds
directly to one or more key receptors, or must be in close
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Vproximity. In contrast, one or two intervening fibronectin se-
quences are apparently not close in the folded protein. The
slightly different profile ofinhibition for cell migration as op-
posed to matrix assembly involving increased relative sensi-
tivity of migration to 12114 (Fig. 5) suggests the possibility
of slightly different types of receptor interaction with this
synergistic region of fibronectin.
An attractive but unproven hypothesis that could explain
all of our immunological and mutagenesis results, is that the
«5O, fibronectin receptor binds directly to both the RGD
site and the synergistic region. Approaches to evaluate this
hypothesis would include determination of the three-dimen-
sional molecular structure of the entire fibronectin cell-
binding domain by x-ray crystallography or nuclear mag-
netic resonance spectroscopy, as well as chemical crosslink-
ing experiments. It is of interest that an x-ray inactivation
study attempting to determine the minimal functional size of
the cell-binding site of the fibronectin molecule estimated a
polypeptide target size of 32 W, rather than only the RGD
tripeptide sequence (56). This target size of 32 kD is quite
close to that of the 34-37-kD protease-resistant domain de-
scribed by Skorstengaard et al. (47) and characterized bio-
logically and immunologically in the present paper.
Our characterization ofthe mAb 3118 site does not exclude
the possibility that other cell-binding sites in the fibronectin
molecule can be important for cell adhesion. The cell-
binding site located in the IIICS region (21) is important for
the adhesion ofmelanoma cellsand other cells derived from
the neural crest. The adhesion-promoting sites in the hep-
arin-binding domain can also be important for certain cell
types, especially for the formation of focal contacts and
microfilament bundles (24, 32, 51). Although none of these
other sites have been shown to interact with the high affinity
ai50, integrin fibronectin receptor as do the sites contained
in the 37-kD fragment, it will be important to extend studies
on fibronectin-mediated cell adhesion to determine if any
or all of these various cell interaction sites on fibronectin
can interact in an independent, cooperative, or synergistic
fashion .
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